Publish With Us
For Authors
For Reviewers
Submit Manuscript
Publisher Information
About This Journal
Aims and Scope
About the Editors
Contact Us
Current Issue
Past Issues
"ID" The Images
Board Review
Pharmacy Collaboration
Publish With Us
For Authors
For Reviewers
Submit Manuscript
Publisher Information
About This Journal
Aims and Scope
About the Editors
Contact Us
Search for:
Board Review: HIV nPEP
1.
According to the 2025 CDC guidelines for nonoccupational postexposure prophylaxis (nPEP), which of the following represents a preferred regimen for most adults and adolescents without contraindications?
A) Zidovudine plus lamivudine
B) Lopinavir/ritonavir plus tenofovir disoproxil fumarate/emtricitabine
C) Bictegravir/emtricitabine/tenofovir alafenamide
D) Efavirenz plus emtricitabine/tenofovir disoproxil fumarate
None
2.
According to the 2025 CDC guidelines regarding nonoccupational postexposure prophylaxis (nPEP), what is the recommended approach for individuals assessed for nPEP who are identified as having potential ongoing risk of HIV exposure after completing the 28-day nPEP course?
A) Advise them that completing the 28-day nPEP course provides durable immunity.
B) Recommend repeat 28-day nPEP courses each time a high-risk exposure occurs in the future.
C) Educate them about HIV pre-exposure prophylaxis (PrEP) and create an nPEP-to-PrEP transition plan if indicated.
D) Only discuss risk reduction counseling and defer discussion of other prevention methods until a future visit.
None
3.
According to the 2025 CDC guidelines on nonoccupational postexposure prophylaxis (nPEP), in which of the following scenarios is nPEP generally not recommended, assuming a substantial risk for HIV transmission occurred?
A) The source is known to have HIV but has sustained viral suppression.
B) The source is known to have HIV but is not virally suppressed.
C) The source's HIV status is unknown, but the exposure type is associated with substantial risk (e.g., receptive anal sex).
D) The exposure occurred via sharing injection drug equipment with a person of unknown HIV status.
None
4.
According to the 2025 CDC guidelines on nonoccupational postexposure prophylaxis (nPEP), what is the recommended final laboratory testing strategy for HIV to rule out infection after an exposed person has completed the 28-day nPEP course?
A) A laboratory-based HIV antigen/antibody combination (Ag/Ab) test performed 4–6 weeks after exposure.
B) A rapid (point-of-care) HIV Ag/Ab test performed 12 weeks after exposure.
C) Both a laboratory-based HIV Ag/Ab combination immunoassay and a diagnostic HIV nucleic acid test (NAT) performed 12 weeks after exposure.
D) A diagnostic HIV NAT performed 4–6 weeks after exposure, followed by a laboratory-based Ag/Ab test 6 months after exposure.
None
Time's up
Share
HIV
Take Quiz
HBV
Take Quiz
Prosthetic Joint Infections
Take Quiz
View All Quizzes
Private Practice Infectious disease will be the leader of clinical infectious disease education for clinicians in private practice, with the goal of optimizing care for patients impacted by infectious diseases.
Important Links
About the Editors
For Authors
Contact Us
Subscribe to our newsletter
*
indicates required
Email Address
*
First Name
*
Last Name
*
Role
*
Attending
Fellow
Resident
Other
Copyright @2024 Private Practice Infectious Disease. All rights reserved.
